Intellia Therapeutics’ NTLA-2001 Shows Promising Potential with Positive Phase 1 Data and Accelerated Phase 3 Enrollment
Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 16. Analyst ...